The market currently views Pfizer through the lens of its "COVID hangover" and an impending "patent cliff." However, for long-term investors, the current valuation may represent an attractive entry point based on three primary pillars:
: Trading at approximately 15x to 20x estimated earnings and significantly below its pandemic-era highs, the stock is considered undervalued by several analysts. With a market cap of roughly $153.59 billion , many argue the downside risk is cushioned by the existing pessimistic sentiment. buy pfizer stock
: Pfizer anticipates a $1.5 billion revenue headwind in 2026 due to patent expirations, with these losses projected to accelerate to over $6 billion annually by 2028 . The market currently views Pfizer through the lens